Zydus Cadila gets USFDA nod to market anti-inflammatory drug
New Delhi: Zydus Cadila has received approval from the US health regulator to market anti- inflammatory Diflunisal tablets in America.
"The company has received final approval from the United States Food and Drug Administration (USFDA) to market Diflunisal tablets in the strength of 500 mg", Zydus group firm Cadila Healthcare said in a statement.
The product is a non steroidal anti-inflammatory drug and will be produced at the group's formulations manufacturing facility at Baddi, it added.
"The group now has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs)", Cadila Healthcare said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd